The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · cited 3×
“VEGFA has high affinity to VEGFR2 expressed in endothelial cells.”
BackgroundRole of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
Claesson‐Welsh, L., & Welsh, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12019 · Cited by 868
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Zhao, Y., & Adjei, A. A. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0465 · Cited by 558
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Cited by
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Shen, G., Zheng, F., Ren, D., Du, F., Dong, Q., Wang, Z., Zhao, F., Ahmad, R., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0664-7 · Cited by 658
Liang, L., Hui, K., Hu, C., Wen, Y., Yang, S., Zhu, P., Wang, L., Xia, Y., Qiao, Y., Sun, W., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1093-3 · Cited by 187
Exercise as adjunct therapy in cancer
Ashcraft, K. A., Warner, A. B., Jones, L. W., & Dewhirst, M. W. (2019) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2018.10.001 · Cited by 148
Anti-angiogenic effects of mangiferin and mechanism of action in metastatic melanoma
Delgado-Hernández, R., Hernández-Balmaseda, I., Rodeiro-Guerra, I., Cesar Rodriguez Gonzalez, J., De Wever, O., Logie, E., Declerck, K., Pérez-Novo, C., & Vanden Berghe, W. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000647 · Cited by 29
Metadata
- Authors
- Lin, B., Song, X., Yang, D., Bai, D., Yao, Y., & Lu, N.
- Venue
- Gene
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 654
- Pages
- 77-86
- ISSN
- 0378-1119 (ISSN-L)
- OpenAlex
- W2793605704
- Cited by
- 384
- References
- 22
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. https://app.cochat.ai/papers/10.1016/j.gene.2018.02.026
- The paper
- Lin, B., Song, X., Yang, D., Bai, D., Yao, Y., & Lu, N. (2018). Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. https://doi.org/10.1016/j.gene.2018.02.026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
